Transimmune AG – Physiologic Immunotherapy of Cancer and Auto-aggressive Immunologic Disorders
Transimmune AG is developing novel immunotherapies based on its unique understanding of the physiologic processes underlying the activation of antigen presenting cells. This understanding derives from nearly 30 years of research into the mechanism of action behind Extracorporeal Photopheresis (ECP), arguably the first FDA-approved cellular immunotherapy. ECP is a highly successful immunological treatment used for many years, mainly in cutaneous T cell lymphoma (CTCL), graft versus host disease (GVHD) and organ transplant rejection.
Transimmune has created two core technologies; Transimmunization and Transtolerization. These involve protocols for manipulating the immune system that have been reduced to practice through our mouse-to-man development platform, generating compelling preclinical proof-of-concept data. These technologies have the potential to significantly enhance current ECP practice as well as drive its application more broadly into numerous other indications.
Transimmune is focused on the discovery of physiologic triggers behind the generation of antigen presenting cells and their subsequent modulation for application in the treatment of cancer, viral disease, organ transplant rejection, graft versus host disease (GVHD), hypersensitivity and autoimmune/auto-inflammatory diseases.
Meet our people, an international group of individuals with outstanding scientific and business backgrounds who bring considerable breadth of experience to Transimmune AG.
Transimmune AG is collaborating with leading academic centers in Europe and the United States. The company is supported by HS LifeSciences, an experienced investor and co-developer of novel biotechnologies.